04.19.24
RevolKa Ltd., a venture-backed biotech company with a protein engineering technology platform, and La Jolla Institute for Immunology (LJI) have initiated a research collaboration to create antigens for next-generation vaccines to address unmet medical needs in infectious diseases.
RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein, which is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. LJI and RevolKa will synergize LJI’s deep knowledge of immunology and RevolKa’s power of AI-driven protein engineering.
Financial terms of this collaboration were not disclosed.
RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein, which is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. LJI and RevolKa will synergize LJI’s deep knowledge of immunology and RevolKa’s power of AI-driven protein engineering.
Financial terms of this collaboration were not disclosed.